Onconova Therapeutics Stock Fundamentals
| ONTXDelisted Stock | USD 1.02 0.04 3.77% |
Onconova Therapeutics fundamentals help investors to digest information that contributes to Onconova Therapeutics' financial success or failures. It also enables traders to predict the movement of Onconova Stock. The fundamental analysis module provides a way to measure Onconova Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Onconova Therapeutics stock.
Onconova |
Onconova Therapeutics Company Return On Equity Analysis
Onconova Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Onconova Therapeutics Return On Equity | -0.84 |
Most of Onconova Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconova Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Onconova Therapeutics has a Return On Equity of -0.843. This is 96.48% lower than that of the Pharmaceuticals sector and 97.69% lower than that of the Health Care industry. The return on equity for all United States stocks is 171.94% higher than that of the company.
Onconova Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Onconova Therapeutics's current stock value. Our valuation model uses many indicators to compare Onconova Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Onconova Therapeutics competition to find correlations between indicators driving Onconova Therapeutics's intrinsic value. More Info.Onconova Therapeutics is regarded fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Onconova Therapeutics' earnings, one of the primary drivers of an investment's value.Onconova Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onconova Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onconova Therapeutics could also be used in its relative valuation, which is a method of valuing Onconova Therapeutics by comparing valuation metrics of similar companies.Onconova Therapeutics is currently under evaluation in return on equity category among its peers.
Onconova Fundamentals
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 92.50 X | |||
| Revenue | 226 B | |||
| Gross Profit | 226 K | |||
| EBITDA | (20.3 T) | |||
| Net Income | (18.95 T) | |||
| Cash And Equivalents | 46.53 M | |||
| Cash Per Share | 2.23 X | |||
| Debt To Equity | 1.26 % | |||
| Current Ratio | 7.43 X | |||
| Book Value Per Share | 0.69 X | |||
| Cash Flow From Operations | (17.93 T) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 8.33 | |||
| Number Of Employees | 16 | |||
| Beta | 1.35 | |||
| Market Capitalization | 20.9 M | |||
| Total Asset | 22.68 T | |||
| Retained Earnings | (482.63 T) | |||
| Working Capital | 31.3 M | |||
| Current Asset | 23.18 M | |||
| Current Liabilities | 7.61 M | |||
| Z Score | -32.73 | |||
| Net Asset | 22.68 T |
About Onconova Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onconova Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onconova Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onconova Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |